HGS Sends New Genomics-Derived Drug To Clinical Testing | GenomeWeb

ROCKVILLE, Md.--Human Genome Sciences here has announced what it claims is the first genomics-derived drug to enter clinical testing. The company filed an Investigational New Drug (IND) application last month and will soon begin enrolling patients in a Phase I study of a human protein that may improve chemotherapy treatments.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.